CRSP vs. DNLI, ABCM, VIR, PCVX, DNA, BEAM, IMCR, RVMD, IMVT, and RLAY
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Denali Therapeutics (DNLI), Abcam (ABCM), Vir Biotechnology (VIR), Vaxcyte (PCVX), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Immunocore (IMCR), Revolution Medicines (RVMD), Immunovant (IMVT), and Relay Therapeutics (RLAY). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics vs.
CRISPR Therapeutics (NASDAQ:CRSP) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
CRISPR Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
Denali Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Denali Therapeutics has a net margin of -300.55% compared to CRISPR Therapeutics' net margin of -54,271.70%. CRISPR Therapeutics' return on equity of -31.85% beat Denali Therapeutics' return on equity.
CRISPR Therapeutics presently has a consensus price target of $74.59, suggesting a potential upside of 67.76%. Denali Therapeutics has a consensus price target of $54.58, suggesting a potential upside of 133.96%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than CRISPR Therapeutics.
CRISPR Therapeutics received 10 more outperform votes than Denali Therapeutics when rated by MarketBeat users. However, 67.14% of users gave Denali Therapeutics an outperform vote while only 67.13% of users gave CRISPR Therapeutics an outperform vote.
71.5% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Denali Therapeutics shares are held by institutional investors. 5.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 12.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, CRISPR Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 8 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.46 beat CRISPR Therapeutics' score of 0.30 indicating that Denali Therapeutics is being referred to more favorably in the news media.
Summary
Denali Therapeutics beats CRISPR Therapeutics on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
